Drug Trial Radar · NCT05995964
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
507
Actual
Start
Aug 22, 2023
Primary completion
Nov 12, 2026
Study completion Apr 1, 2027
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Aug 16, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash, caused by a skin reaction. This study is seeking participants who: * are 18 years of age or more. * Were confirmed to have AD at least 6 months ago. * Are not having an effective treatment result from medicines that are applied on skin for AD. * Are considered by their doctors to have moderate to severe AD. In Stage 1 of the study, participants will receive either PF-07275315 or PF-07264660 or placebo. Stage 1 is complete. In Stage 2 of the study participants will receive either PF-07275315 or placebo. In Stage 3 of the study participants who have received anti-inflammatory proteins, will receive either PF-07275315 or placebo. In Stage 4 of the study participants will receive either PF-07264660 or placebo. A placebo does not have any medicine in it but looks just like the medicines being studied. PF-07275315 or PF-07264660 or placebo will be given as multiple shots in the clinic over the course of each Stage. The experiences of people receiving PF-07275315 or PF-07264660 will be compared to people who do not. This will help determine if PF-07275315 and PF-07264660 are safe and effective. Participants in Stages 1, 2 and 4 will be involved in this study for up to 40 weeks (10 months). Participants in Stage 3 will be involved in this study for up to 52 weeks (13 months).
Conditions
- Atopic Dermatitis
Interventions
PF-07275315Drug
subcutaneous injection
PF-07264660Drug
subcutaneous injection
PlaceboOther
subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- The number of participants achieving ≥75% improvement in EAS175 from baseline at week16.Time frame: Week 16
Locations
96 sites in 7 countries. Site status is shown where the registry gives one.
Allervie Clinical Research
Birmingham, Alabama
Onyx Clinical Research - Peoria
Peoria, Arizona
Onyx Clinical Research
Phoenix, Arizona
Banner - University Medicine Dermatology Clinic
Tucson, Arizona
Marvel Clinical Research
Huntington Beach, California
California Allergy and Asthma Medical Group
Los Angeles, California
University Dermatology Trials, INC.
Newport Beach, California
Northridge Clinical Trials
Northridge, California
Profound Research LLC
Oceanside, California
Dermatology Cosmetic Laser Medical Associates of La Jolla, Inc.
San Diego, California
West Dermatology La Jolla
San Diego, California
Sunwise Clinical Research
Walnut Creek, California
AboutSkin Research, LLC
Greenwood Village, Colorado
Renaissance Research and Medical Group
Cape Coral, Florida
Florida International Medical Research
Coral Gables, Florida
Revival Research
Doral, Florida
St. Jude Clinical Research
Doral, Florida
SouthCoast Research Center
Miami, Florida
Floridian Research Institute Llc
Miami, Florida
Global Health Research Center, Inc.
Miami Lakes, Florida
Ziaderm Research LLC
North Miami Beach, Florida
Clinical Neuroscience Solutions, Inc.
Orlando, Florida
GCP Research, Global Clinical professionals
St. Petersburg, Florida
ForCare Clinical Research
Tampa, Florida
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana
Southern Indiana Clinical Trials
New Albany, Indiana
Maryland Laser Skin and Vein
Hunt Valley, Maryland
Michigan Center for Research Company
Clarkston, Michigan
MI Skin Innovations
Northville, Michigan
Revival Research Institute LLC
Troy, Michigan
Skin Specialists, PC dba Schlessinger MD
Omaha, Nebraska
Empire Dermatology
East Syracuse, New York
Private Practice - Dr. Bobby Buka
New York, New York
Icahn School of Medicine at Mount Sinai
New York, New York
Sadick Research Group
New York, New York
Apex Clinical Research Center
Mayfield Heights, Ohio
Epic Medical Research - Oklahoma
Chickasha, Oklahoma
Unity Clinical Research
Oklahoma City, Oklahoma
Vital Prospects Clinical Research Institute, PC
Tulsa, Oklahoma
Velocity Clinical Research, Medford
Medford, Oregon
Showing 40 of 96 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.